SCHEMBL5032376

SCHEMBL5032376

N#CC(N)c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
KCNA5 P22460 5/20 0.44
KCNE1 P15382 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
KCNH2 Q12809 1/20 0.42
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.40
CYP2D6 P10635 1/20 0.40
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
PI4KA P42356 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38
PI4K2A Q9BTU6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6754281 0.98 SMN1; SMN2 (0.44) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL6654893 0.84 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL5429300 0.78 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL2937192 0.78 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL31482123 0.77 SMN1; SMN2 (0.41) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL7477684 0.75 TRPA1 (0.48) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL29700907 0.75 SMN1; SMN2 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL5581899 0.75 SMN1; SMN2 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL22275828 0.75 SMN1; SMN2 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1
SCHEMBL702161 0.75 SMN1; SMN2 (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed
US-6759428-B2 SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS ROCHE PALO ALTO LLC 2004-07-06 US disclosed
US-20040077646-A1 Indole nitriles ROCHE PALO ALTO LLC 2004-04-22 US disclosed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB SLC6A2 4864/4885SLC6A4 4764/4885SLC6A3 4513/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B SLC6A2 3358/4885SLC6A4 3889/4885SLC6A3 3548/4885
US-20040077646-A1 Indole nitriles TPH1, IDO1, NAT1 SLC6A2 388/4885SLC6A4 108/4885SLC6A3 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.